[ad_1]
Washington D.C., Sept. 30: A study reveals that aspirin could play a vital role in the treatment of cancer.
Peter Elwood of Cardiff University, who led the study, said the use of low-dose aspirin as a preventive agent against heart disease, stroke and cancer was well established, cancer also.
The systematic review, which looked at the survival of 120,000 cancer patients who took aspirin, versus 400,000 non-patients, showed that at any time after the diagnosis of certain cancers the proportion of patients still alive was 20 to 30%. greater in those who take the drug.
The spread of cancer to other parts of the body has also been significantly reduced in patients using aspirin.
One of the colon cancer studies reviewed by the researchers suggests that a non-diabetic man of about 65 years of age who is taking aspirin would have a prognosis similar to that of a five-year-old man. years who does not take any. For a woman of the same age with colon cancer, the addition of aspirin could result in a similar prognosis in a woman four years younger.
Nearly half of the studies included in the review involved patients with colon cancer and most other studies involved patients with breast or prostate cancer. Very few studies have been conducted on patients with other less common cancers, but overall, the pooled data for all cancers suggest a benefit of aspirin.
"Patients with cancer should receive the evidence available and be helped to get an idea of the balance between the risks and benefits of a low daily dose." Evidence from other studies is urgently needed and patients should be strongly encouraged to participate in. Appropriate research studies.All patients should consult their physician before starting a new drug, "concluded Elwood.
The study is published in Plos One Medicine.
Source link
